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Abstract Previous studies of glucocorticoid (GC) therapy
and mortality have had inconsistent results and have not
considered possible perimortal bias—a type of protopathic
bias where illness in the latter stages of life influences GC
exposure, and might affect the observed relationship
between GC use and death. This study aimed to investigate
all-cause and cause-specific mortality in association with
GC therapy in patients with rheumatoid arthritis (RA), and
explore possible perimortal bias. A retrospective cohort
study using the primary care electronic medical records.
Oral GC exposure was identified from prescriptions.
Mortality data were obtained from the UK Office for
National Statistics. Multivariable Cox proportional hazards
regression models assessed the association between GC use
models and death. Several methods to explore perimortal
bias were examined. The cohort included 16,762 patients.
For ever GC use there was an adjusted hazard ratio for all-
cause mortality of 1.97 (95 % CI 1.81–2.15). Current GC
dose of below 5 mg per day (prednisolone equivalent dose)
was not associated with an increased risk of death, but a
dose–response association was seen for higher dose cate-
gories. The association between ever GC use and all-cause
mortality was partly explained by perimortal bias. GC
therapy was associated with an increased risk of mortality
for all specific causes considered, albeit to a lesser extent
for cardiovascular causes. GC use was associated with an
increased risk of death in RA, at least partially explained
by perimortal bias. Importantly, GC doses below 5 mg
were not associated with an increased risk of death.
Keywords Rheumatoid arthritis  Glucocorticoids 
Mortality  Steroids
Introduction
Rheumatoid arthritis (RA) is a chronic inflammatory dis-
ease which affects between 0.5 and 1 % of the adult pop-
ulation worldwide [1–3]. Oral glucocorticoid (GC) therapy
was introduced as a treatment for patients with RA nearly
60 years ago [4] and is still used widely. Around one third
of patients with RA are current users, and two thirds of
patients have ever used GCs [5]. GCs improve symptoms
of active RA through reducing joint pain, swelling and
stiffness [6]. However, there are some concerns about their
potential side effects including cardiovascular (CV) events,
diabetes, infection, fracture, and cataracts [7–11], many of
which are associated with an increased risk of mortality.
Previous studies have investigated the association
between GC therapy and mortality, mostly focusing on all-
cause mortality, though some have investigated CV mor-
tality [5, 12–16]. Findings from these studies are not con-
sistent. GCs have been associated with an increased risk of
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all-cause mortality in some [12–15, 17, 18] but not all
studies [16, 19, 20], with similar inconsistency for CV
mortality [12, 14, 16]. Very few studies have examined
other cause-specific mortality. In studies that consider
dose, some have suggested no association with doses
\5 mg prednisolone equivalent [12, 13], reflecting either a
lack of significant side effects at this dose or perhaps a
favourable balance between side effects and positive anti-
inflammatory properties.
There are important methodological issues when con-
sidering GC exposure and mortality, including confound-
ing by indication—whereby GC therapy is given to patients
with high disease severity and high disease severity is itself
associated with increased mortality. However, studies have
rarely considered a form of protopathic bias we will call
‘perimortal bias’, where illness in the latter stages of life
influences GC exposure, and which consequently might
affect the observed relationship between GC use and death.
For example, if a patient were to develop cancer, GC
therapy may be prescribed to treat the malignancy and a
resultant association would be observed between GCs and
(cancer-specific) mortality. The aim of this study was to
investigate all-cause and cause-specific mortality in asso-
ciation with various models of oral GC exposure in patients
with RA, and to explore and control for the possible
existence of perimortal bias.
Methods
Database
The Clinical Practice Research Datalink (CPRD) is a
database of anonymised UK primary care electronic med-
ical records covering 9 % of the population. There are 650
General Practitioner (GP) practices who contribute high-
quality data, with over 5.5 million active patients who are
broadly representative of the UK population [21, 22].
Information on the database includes patient demographics,
medical diagnoses, clinical tests, hospital referrals, and
drug prescriptions. Diagnoses on CPRD have been shown
to have a high validity [23]. Selected practices consent to
linkage to mortality data for England and Wales from the
UK Office for National Statistics (ONS), and to Hospital
Episode Statistics (HES), which provides information on
hospital admissions.
Study population
Patients with RA were identified in the CPRD database
using a validated algorithm [24]. To satisfy the algorithm
patients needed either: more than one RA Read code, a
seropositive/erosive RA or ‘‘rheumatoid arthritis’’ code
(such as RA of knee), and no code for an alternative
diagnosis after the last RA code; or a DMARD prescription
with no Read code for an alternative indication in the
5 years prior to the first DMARD prescription. A study
window of 1st January 1998–1st October 2011 was used.
The cohort was restricted to the 340 GP practices eligible
to be linked to ONS mortality and HES data, with data
restricted to the period of mortality data linkage for each
GP practice to ensure accurate vital status information.
Patients entered the study on the latest of first RA code,
date of ONS linkage or 01/01/1998. Patients under
16 years of age were excluded. The population was also
restricted to patients with at least 1 year’s information in
CPRD prior to cohort entry, to allow assessment of prior
GC exposure. Follow-up ended at transfer out of GP
practice, GP practice data last collection, death, or 01/10/
2011, whichever came first.
Exposure definition
The dose and duration of each GC prescription was derived
from the available prescription information using a pre-
specified algorithm (see Online Resource item A1). Doses
of oral GCs were converted into a prednisolone-equivalent
dosage (PED). Time-varying GC exposure was then
defined in six ways: (1) ever use: a patient was considered a
never user until the point of their first GC prescription
when they became an ever user. This was the primary
analyses. (2) Current use: a patient was considered a cur-
rent user during their GC prescription and became a non-
user during the periods without a GC prescription. (3)
Current dose (5 mg/day): during a patient’s GC prescrip-
tion this was the dose divided by 5, during non-use this was
zero. (4) Current dose category: a patient’s current dose
was categorised into the following categories: non-use,
[0–4.9, 5–7.4, 7.5–14.9, 15–24.9 and 25 mg and over
PED/day. (5) Cumulative dose since cohort entry
(1000 mg/day): a patient’s cumulative dose was calculated
by summing the doses that had been prescribed up to that
point and dividing by 1000, during non-use the cumulative
dose would remain at the cumulative dose of prescriptions
up to that point. (6) Cumulative dose category: a patent’s
cumulative dose was categorised into the following cate-
gories: non-use, [0–959, 960–3054, 3055–7299 and
7300 mg and over PED/day. An example of a patient’s
changing GC status through time is shown in Fig. 1. As
time in hospital creates a gap in primary care records,
because patients cannot attend the primary care practice,
the GC exposure was set to the latest GC status prior to
admission for the duration of any hospital inpatient stay
identified using HES data.
1046 M. Movahedi et al.
123
Death ascertainment
The ONS defines cause of death by International Classifi-
cation of Diseases version 2010 (ICD 10) codes with a
specified underlying cause of death. We examined the
underlying cause of death by the most frequent ICD 10
chapter headings of circulatory (ICD chapter I), neoplasms
(ICD chapters C and D), respiratory diseases (ICD chap-
ter J), and the remaining chapter headings grouped together
in an ‘‘other causes’’ category. We also identified the
leading causes of death in each chapter. Causes of death
prior to 2001 were coded using ICD 9 and were later
mapped to ICD 10.
Confounders
The following a priori potential confounders were included
in the analyses: gender, age, body mass index (BMI),
smoking status, socioeconomic status (SES) (Townsend
quintile), prior 1 year cumulative GC dose at baseline,
baseline Charlson comorbidity index [25], time-varying
use of the DMARDs methotrexate, hydroxychloroquine,
sulfasalazine and leflunomide and use of other DMARDs
(penicillamine, azathioprine, cyclosporin, injectable gold)
and time-varying use of non-steroidal anti-inflammatory
drugs (NSAIDs) during follow-up. For a subgroup of the
cohort who had the information available, the mean num-
ber of rheumatology outpatient visits per year and the mean
number of GP visits per year was calculated and addi-
tionally adjusted for in a sensitivity analysis.
Statistical analysis
Baseline characteristics were tabulated for the whole
cohort, and stratified by ever use at the end of follow-up, to
examine if there were any differences between ever users
and never users.
Mortality rates with 95 % confidence intervals (CI) were
estimated by dividing the number of deaths by the total
number of person-years follow-up.
Primary analyses examined the association between GC
exposure and time until death, using Cox proportional
hazards regression [26], using the six GC exposure defi-
nitions described above. Associations between GC expo-
sure and mortality (both all-cause and cause-specific) were
estimated through crude, and fully adjusted hazard ratios
(HR), with 95 % CI. The proportional hazards assumption
was checked by testing the Schoenfeld residuals. The
association between oral GC use and cause-specific mor-
tality was further explored using the Fine and Gray com-
peting risks approach [27]. All data analysis was performed
using Stata/MP Version 12.1 (StataCorp, Texas).
Missing data
The proportion of missing data for all confounders was
assessed. If there was more than 5 % missing data the
Fig. 1 Example of GC exposure definitions during follow-up for a hypothetical patient
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variable was included in a fully adjusted model 1, and
assessed in a complete case analysis. Any variable that was
significantly associated with the outcome or changed the
hazard ratio for the primary exposure by at least 10 % was
included in the analyses, and therefore imputed. Other
variables were excluded from the analysis. If there was
\5 % missing data the variable was included in the model,
and only complete cases were included in the analyses.
Exploring potential perimortal bias
Possible perimortal bias was explored in three ways. First, in
order to explore whether GC therapy was being initiated in
response to a terminal illness such as cancer, the distribution of
cause-specific deaths in the first 6 months after GC initiation
was compared to the distribution of cause-specific deaths
more than 6 months after GC initiation in ever GC users.
Second, the proportion of deaths was compared among two
groups: (1) GC users who had oral GC therapy less than
6 months before death; and (2) GC users who had oral GC
therapy more than 6 months before death but no GC use in the
6 months prior to death. Third, exposure during a 6 month
period before death was excluded from the analyses to see if
this had an impact on the results [28]. The same GC exposure
models were used, although now based on the GC status at
6 months prior to death (see Figure A1 in Additional file 2).
The protocol for this study has been approved by
Independent Scientific Advisory Committee for Medicines
and Healthcare Regulatory Agency database research
(Protocol number: 11_113RA4). As this study used rou-
tinely collected anonymised electronic health records
consent was not required.
Results
There were 37,983 patients identified with a diagnosis of
RA, of whom 21,355 were eligible for ONS linkage. After
applying the exclusion criteria, the cohort reduced to
16,762 patients (Fig. 2). Table 1 summarizes the patient
characteristics of the whole cohort, ever GC users and non-
users. 70 % of patients were female, with similar propor-
tions in the GC and non-GC groups. Mean age at baseline
was 60.2 years [standard deviation (SD): 14.6].
There were 8367 (50 %) patients who received at least
one prescription for oral GCs. These patients were on
average 4 years older, more likely to have received GCs in
the 1 year prior to RA (44 vs. 6 %, respectively) and had
higher DMARD use during follow-up compared to non-
users. The mean baseline Charlson comorbidity index was
slightly higher in ever users compared with never users
(1.39 vs. 1.25) (Table 1).
During active GC prescriptions, the mean current daily
dose (PED) was 7.5 mg (SD 6.9 mg). The mean cumula-
tive dose (PED) among the 8367 patients who received GC
therapy was 5.3 g (SD 6.0 g).
During a total of 111,099 person years, 2996 patients
died (median follow-up of 6.1 years per person), giving an
all-cause mortality rate of 27.0 deaths per 1000 person-
years (pyrs) (95 % CI 26.0–28.0) (Table 2). In those never
exposed to GCs the mortality rate was 15.5 deaths per 1000
pyrs, compared to 44.0 deaths per 1000 pyrs in those ever
exposed to GCs.
Overall the most common cause of death was cardio-
vascular disease, followed by neoplasms and respiratory
diseases. The underlying causes of death in the ‘‘other
causes’’ category were mostly musculoskeletal (28.0 %).
Figure 3 shows the cumulative incidence curves from Fine-
Gray models [27] for the four categories of cause-specific
mortality. Ever users had higher mortality rates in each
cause-specific category compared to never users. For each
category the mortality rate for ever users was higher than
never users from the start of follow-up, and the mortality
rate was consistent through follow-up for both exposed and
unexposed groups.
Cardiovascular mortality rates were 15.8 deaths per
1000 pyrs in ever users compared to 6.4 deaths per 1000
pyrs in never users. Within this chapter, ischemic heart
disease had the highest mortality rate for both ever and
never users. Neoplasms had the second highest mortality
rate for ever GC users. Conversely, the second highest
mortality rate for never users was other causes of death.
Respiratory diseases had the lowest mortality rate in both
ever and never GC users (Table 2).
Fig. 2 Flowchart of the ONS linked patient cohort
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Table 3 shows the associations between oral GC use and
risk of all-cause and cause-specific mortality, estimated
through six alternative Cox models, adjusted for age,
gender, smoking status, SES, prior cumulative dose of GC,
baseline Charlson comorbidity index, time-varying NSAID
use and time-varying DMARD use.
BMI was the only potential confounder with higher than
five percent of missing data (Table 1). When it was
included in a complete case analysis of model 1 it did not
alter the hazard ratio for GC use and was not significantly
associated with mortality and so was not included in the
fully adjusted models. Smoking and SES had\5 % miss-
ing data and were included in the fully adjusted models. All
models consistently showed that risk of death was associ-
ated with GC use and increased with higher dosages of
GCs. There was a nearly twofold greater risk of all-cause
mortality in ever users, compared to never users (HR 1.97,
95 % CI 1.81–2.15). For cause-specific mortality, ever
users had over a three times higher risk of death from
neoplasms compared to never users (HR 3.20, 95 % CI
2.66–3.86). For both all-cause and cause-specific mortality,
a similar pattern was seen for current use, though the point
estimates were lower. For each 5 mg increase in GC dose
there was a 33 % increased risk of all-cause mortality
compared to non-users (HR 1.33, 95 % CI 1.30–1.35).
Similar increased risks were seen for each of the cause
specific mortality categories, with the highest risk seen for
neoplasms (HR 1.46, 95 % CI 1.42–1.49).
The categorisation of current daily dose showed that for
all-cause mortality, CV mortality and mortality due to
respiratory diseases, a dose below 5 mg per day was not
associated with an increased risk of death. Furthermore, for
neoplasms and ‘other causes’, a dose of below 7.5 mg per
day was not associated with an increased risk of death.
However, as current daily dose increased above these
doses, so too did the risk of death. Comparing between the
hazard ratios for cause-specific mortality, the risk of car-
diovascular mortality was notably lower than for the other
three categories of death, for current GC dose above
7.5 mg.
There was a 6 % increased risk of all-cause mortality for
each 1000 mg/day increase in cumulative dose since cohort
Table 1 Characteristics of the
cohort, stratified by oral GC
therapy status during follow-up
All subjects Never users Ever users
Number of patients, n (%) 16,762 8395 (50.1) 8367 (49.9)
Follow-up time, total (person-years) 111,099 66,560 44,538
Females, n (%) 11,748 (70.1) 5945 (70.8) 5803 (69.4)
Age at baseline (years), mean (SD) 60.2 (14.6) 58.2 (14.9) 62.1 (14.1)
Body Mass Index at baseline
Mean (SD) 26.8 (5.6) 26.9 (5.5) 26.8 (5.71)
Missing (%) 2763 (16.5) 1483 (17.7) 1280 (15.3)
Smoking status at baseline, n (%)
Non smoker 7832 (46.7) 4115 (49.0) 3717 (44.4)
Ex smoker 3192 (19.0) 1489 (17.7) 1703 (20.4)
Current smoker 5227 (31.2) 2525 (30.1) 2702 (32.3)
Missing 511 (3.1) 266 (3.17) 245 (2.93)
Socioeconomic status quintile at baseline, n (%)
First (least deprived) 3672 (21.9) 1871 (22.3) 1801 (21.5)
Second 4040 (24.1) 2031 (24.2) 2009 (24.5)
Third 3566 (21.3) 1746 (20.8) 1820 (21.8)
Fourth 3213 (19.2) 1601 (19.1) 1612 (19.3)
Fifth (most deprived) 2204 (13.2) 1112 (13.3) 1092 (13.1)
Missing 67 (0.4) 34 (0.4) 33 (0.4)
Prior history of GC use, n (%) 4138 (24.7) 484 (5.80) 3661 (43.8)
Charlson comorbidity index at baseline, mean (SD) 1.32 (0.70) 1.25 (0.64) 1.39 (0.76)
Methotroxate ever during follow-up, n (%) 8949 (53.4) 4020 (47.9) 4929 (58.9)
Hydroxycholoroquine ever during follow-up, n (%) 3728 (22.2) 1726 (20.6) 2002 (23.9)
Sulfasalazine ever during follow-up, n (%) 4793 (28.6) 2249 (26.8) 2544 (30.4)
Leflunomide ever during follow-up, n (%) 1465 (8.74) 455 (5.42) 1010 (12.1)
Other DMARDs ever during follow-up, n (%)a 4304 (25.7) 1683 (20.1) 2621 (31.3)
a Other DMARDS: penicillamine, azathioprine, cyclosporin, injectable gold
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Table 2 Underlying causes of death and crude mortality rates, overall and by ever GC use status
All subjects Never GC useb Ever GC use
Events (%) Mortality ratea Events (%) Mortality ratea Events (%) Mortality ratea
1 All-causes 2996 27.0 (26.0–28.0) 1034 15.5 (14.6–16.5) 1962 44.0 (42.1–46.0)
2 Cardiovascular diseases 1131 (100) 10.2 (9.60–10.8) 428 (100) 6.40 (5.84–7.07) 703 (100) 15.8 (14.7–17.0)
Ischemic heart diseases 581 (51.4) 5.23 (4.82–5.67) 207 (48.4) 3.11 (2.61–3.37) 374 (53.2) 8.39 (7.59–9.29)
Cerebrovascular diseases 247 (21.8) 2.22 (1.96–2.52) 121 (28.3) 1.82 (1.52–2.17) 126 (17.9) 2.83 (2.37–3.37)
Others 303 (26.8) 2.73 (2.44–3.05) 100 (23.3) 1.50 (1.24–1.83) 203 (28.9) 4.56 (3.97–5.23)
3 Neoplasms 639 (100) 5.75 (5.32–6.22) 191 (100) 2.87 (2.49–3.31) 448 (100) 10.1 (9.17–11.0)
Respiratory neoplasm 208 (32.6) 1.87 (1.63–2.14) 41 (21.5) 0.62 (0.45–0.84) 167 (37.3) 3.75 (3.22–4.36)
Digestive neoplasm 135 (21.1) 1.22 (1.03–1.44) 46 (24.1) 0.69 (0.52–0.92) 89 (19.9) 2.00 (1.62–2.46)
Others 296 (46.3) 2.66 (2.38–2.99) 104 (54.4) 1.56 (1.29–1.89) 192 (42.8) 4.31 (3.74–4.97)
4 Respiratory diseases 509 (100) 4.58 (4.20–5.00) 132 (100) 1.98 (1.67–2.35) 377 (100) 8.46 (7.65–9.36)
Respiratory infection 216 (42.4) 1.94 (1.70–2.22) 80 (60.6) 1.20 (0.97–1.50) 136 (36.1) 3.05 (2.58–3.61)
Lower respiratory diseases 205 (40.3) 1.85 (1.61–2.12) 32 (24.2) 0.48 (0.34–0.68) 173 (45.9) 3.88 (3.35–4.51)
Others 88 (17.3) 0.79 (0.64–0.98) 20 (15.2) 0.30 (0.19–0.47) 68 (18.0) 1.53 (1.20–1.94)
5 Others causes of death 717 (100) 6.45 (6.00–6.94) 283 (100) 4.25 (3.78–4.77) 434 (100) 9.74 (8.87–10.7)
Musculoskeletal diseases 201 (28.0) 1.81 (1.58–2.08) 67 (23.7) 1.00 (0.79–1.28) 134 (30.9) 3.01 (2.54–3.56)
Digestive diseases 158 (22.0) 1.42 (1.22–1.66) 68 (24.0) 1.02 (0.81–1.29) 90 (20.7) 1.64 (1.79–2.48)
Genitourinary diseases 75 (10.5) 0.68 (0.54–0.85) 22 (7.8) 0.33 (0.22–0.50) 53 (12.2) 1.19 (0.91–1.56)
Injury, poisoning and external causes 102 (14.2) 0.92 (0.76–1.11) 47 (16.6) 0.71 (0.53–0.93) 55 (12.7) 1.23 (0.95–1.61)
Others 181 (25.3) 1.63 (1.41–1.88) 79 (27.9) 1.19 (0.95–1.48) 102 (23.5) 2.29 (1.89–2.78)
a Mortality rates per 1000 patient-years
b Patients who had not yet used GCs could initially contribute person time to the ‘never GC use’ group, and then switch to ‘ever GC use’ person
time on receipt of their first GC prescription
Fig. 3 Cumulative incidence
curves by GC status
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entry (HR 1.06, 95 % CI 1.05–1.07). Similar increases in
risk were seen for each cause-specific mortality category.
Categorisation of cumulative dose showed a dose response
increased risk of all-cause mortality in each category of
cumulative dose, with risk of death increasing with
increased categories of cumulative dose. The exception to
this was for other causes of death, where there was not an
increased risk of death from other causes with cumulative
doses up to 3054.9 mg (Table 3). Additional adjustment
for mean number of rheumatology outpatient visits per year
and mean number of GP visits per year in general increased
the risk of all-cause mortality and cause-specific mortality,
but did not alter the significance, except for the lowest
current dose category (0-4.9 mg) where a significantly
reduced risk of mortality due to neoplasms was seen
(Online resource Table A1).
Perimortal bias
The mortality rate in the first 6 months following GC
therapy initiation was 56.5 deaths per 1000 pyrs, compared
to 42.8 deaths per 1000 pyrs beyond 6 months after GC
initiation. The rate of neoplasm deaths was higher in
patients in the first 6 months following GC initiation (23.5
per 1000 pyrs compared to 8.7 per 1000 pyrs beyond
6 months) (Online Resource Table A2).
Of those who died (N = 2996), 1962 patients ever used
GCs. Of these, 1576 patients used GCs during the 6 months
prior to death and 368 last used GCs more than 6 months
prior to death. Those who used GC in the 6 months prior to
death had a higher proportion of deaths due to respiratory,
neoplasms and other causes, but a lower proportion of CV
deaths, compared to those patients who received GC
therapy more than 6 months prior to death. For example
23.4 % of those who used GCs during the 6 months prior
to death died from neoplasms, compared to 20.7 % in those
who used GCs more than 6 months prior to death (Online
Resource Table A3).
After the exclusion of GC information in the 6 months
prior to death, the association between ever use and all-
cause mortality was reduced but remained statistically
significant (HR 1.64, 95 % CI 1.50–1.79). A similar
reduction in hazard ratio was seen for cause-specific mor-
tality, in particular neoplasm mortality where ever users
had only a 76 % increased risk of death from neoplasms
(HR 1.76, 95 % CI 1.47–2.10), compared to a threefold
greater risk when the 6 months prior to death was included
(HR 3.20, 95 % CI 2.66–3.86). In Model 4, the magnitude
of risk was reduced for the highest dose category of
[25 mg PED for all-cause and each cause-specific mor-
tality. Excluding the exposure data from 6 months prior to
death had the biggest impact on deaths caused by
Table 3 Association between oral GC use and all-cause and cause-specific mortality (n = 16,187)












1 Ever use, (ref = never use) 1.97 (1.81–2.15) 1.66 (1.45–1.91) 3.20 (2.66–3.86) 2.64 (2.11–3.31) 1.39 (1.16–1.66)
2 Current use, (ref = non-use) 1.77 (1.62–1.93) 1.58 (1.37–1.83) 2.22 (1.84–2.68) 1.92 (1.57–2.36) 1.69 (1.41–2.02)
3 Current dose per 5 mg/day 1.33 (1.30–1.35) 1.21 (1.16–1.27) 1.46 (1.42–1.49) 1.36 (1.30–1.41) 1.25 (1.20–1.31)
4 Current dose category, (ref = non-use)
[0–4.9 mg 1.02 (0.87–1.20) 1.10 (0.85–1.41) 0.79 (0.51–1.22) 0.87 (0.57–1.33) 1.15 (0.85–1.57)
5.0–7.4 mg 1.44 (1.26–1.64) 1.59 (1.31–1.94) 1.07 (0.75–1.52) 1.74 (1.30–2.32) 1.23 (0.93–1.63)
7.5–14.9 mg 2.24 (1.98–2.54) 1.96 (1.59–2.42) 2.34 (1.75–3.13) 2.19 (1.62–2.97) 2.66 (2.09–3.38)
15.0–24.9 mg 4.50 (3.61–5.62) 2.79 (1.80–4.31) 8.07 (5.41–12.0) 8.03 (5.31–12.2) 2.06 (1.09–3.90)
C25 mg 11.0 (8.87–13.6) 2.48 (1.23–4.99) 31.3 (23.5–41.9) 11.4 (6.84–19.0) 6.87 (4.01–11.8)
5 Cumulative dose since cohort
entry (1000 mg/day)
1.06 (1.05–1.07) 1.05 (1.04–1.07) 1.06 (1.04–1.08) 1.07 (1.05–1.09) 1.07 (1.05–1.08)
6 Cumulative dose category (ref = non-use)
[0–959.9 mg 1.60 (1.42–1.81) 1.41 (1.16–1.72) 2.51 (1.97–3.21) 2.18 (1.61–2.95) 1.04 (0.79–1.36)
960–3054.9 mg 1.83 (1.62–2.07) 1.38 (1.12–1.70) 3.84 (3.04–4.87) 2.24 (1.64–3.05) 1.16 (0.88–1.52)
3055–7299.9 mg 2.11 (1.87–2.39) 1.91 (1.57–2.32) 3.31 (2.55–4.30) 2.65 (1.95–3.61) 1.48 (1.15–1.92)
C7300 mg 3.11 (2.74–3.52) 2.59 (2.11–3.18) 3.85 (2.90–5.10) 4.85 (3.59–6.55) 2.54 (1.98–3.25)
a Adjusted for gender, age, smoking status, SES, prior cumulative dose of GC, Charlson comorbidity index at baseline, time-varying NSAID use
and time-varying DMARD use
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neoplasms, with hazard ratios falling from 8.07 (95 % CI
5.41–12.0) to 3.42 (95 % CI 1.87–6.28) for 15–25 mg, and
from 31.3 (95 % CI 23.5–41.9) to 5.66 (95 % CI
2.80–11.4) for [25 mg. Full results for models 1-6 fol-
lowing exclusion of GC information in the 6 months prior
to detail are shown in Online Resource Table A4.
Unmeasured confounding
The cause-specific analyses found an association between
oral GC use and death from other causes, supporting the
possibility of unmeasured confounding. To explore this, a
post hoc sensitivity analysis was conducted using the rule
out approach [29, 30]. This approach finds the minimum
effect an unmeasured confounder would need to have to
remove statistical significance. It was found that an
unmeasured confounding factor with 40 % prevalence
would have to increase the relative risk of mortality by a
factor 3 and at the same time increase the odds of GC
exposure by a factor of 3.5 in order to fully remove the
association found between ever use and mortality risk due
to other causes (HR 1.39, 95 % CI 1.16–1.66). For each of
the other causes of death the unmeasured confounders
would need to increase the relative risk of mortality and the
odds of GC exposure by too large an amount for them to
explain the result fully. For example, an unmeasured con-
founding factor for CV mortality would have to increase
the relative risk of CV mortality by a factor of 3 and
increase the odds of GC exposure by a factor of 7.7 in order
to remove the association found, which seems unlikely.
Similarly, an unmeasured confounder with increased risk
of death by a factor below 3 cannot plausibly explain the
observed association between GC exposure and CV
mortality.
Discussion
This study examined the association between oral GC
therapy and mortality rates in a cohort of patients with RA
in the UK. Ever GC use and current GC use was associated
with an increased risk of all-cause mortality and cause-
specific mortality, with a largely consistent dose–response
effect. An increase in current dose of 5 mg per day was
associated with an increased risk of death, however cate-
gorisation showed that taking\5 mg per day at the time of
death did not increase the risk of all-cause mortality or
cause-specific mortality, and taking\7.5 mg per day at the
time of death did not increase this risk of death from
neoplasms or other non-CV and non-respiratory causes. In
addition, moderate to high doses of GC therapy were
associated with a lesser risk of CV deaths compared to
neoplasm, respiratory and other causes of death, which
might suggest GC therapy has a less harmful effect on CV
mortality.
The study showed that perimortal bias partially
explained some of the results, especially at higher doses.
Perimortal bias is important to consider for a number of
reasons. GCs can be used to treat diseases that might
develop through the course of follow-up, and where that
disease is the leading cause of death. For example, if a
patient were to develop a malignancy, they might start GC
therapy as part of their cancer treatment which would lead
to a positive association between GCs and (cancer-related)
mortality. Similarly, end of life care might lead to a switch
from disease-modifying anti-rheumatic drug (DMARD)
therapy (that requires regular blood monitoring) to GC
therapy, again generating an association between GC use
and death.
When GC use in the 6 months prior to death was
removed, the association between ever GC use and all-
cause mortality remained significant, but the risks were
reduced. This was mainly influenced by the large reduction
in risk of death from neoplasms, where there is a clear
possibility of perimortal bias: GCs are prescribed as a
treatment for cancer [31]. Initial signals of possible peri-
mortal bias were evident in the magnitude of the associa-
tion between high-dose GCs and risk of death due to
neoplasm (HR 31.3, 95 %CI 23.5–41.9).
The all-cause mortality rate for this study was 27 deaths
per 1000 person-years, and the cardiovascular mortality
rate was 10 deaths per 1000 person-years. This was higher
than a recent cohort study in the UK (Norfolk Arthritis
Registry (NOAR)) [32] where rates were 20–21 per 1000
person-years and 7–8 per 1000 person years for all-cause
mortality and cardiovascular mortality respectively. This
would be expected as NOAR includes patients with early
inflammatory arthritis, whereas this study included patients
with a higher baseline age and with RA only, and therefore
more severe disease.
Our findings are in agreement with some previous
studies [5, 12–15, 17] which have investigated all-cause
mortality or CV mortality in association with GC use.
Caplan et al. [5] found an increased risk of death with
current GC use, with an adjusted odds ratio of 2.2 (95 % CI
1.9–2.7) and an increased risk of death with increasing
duration of GC treatment. del Rincon et al. [12] found a GC
dose-dependent increase in death from all causes (HR 1.07
per 1 mg/day (95 % CI 1.05–1.08) and CV cause with a
similar point estimate. They also showed that there was a
dose response association for cumulative dose for all-cause
and CV mortality with a threshold of 40 g. Listing et al.
[13] showed that GC doses higher than 5.0 mg per day
were significantly associated with increased all-cause
mortality, independent of disease activity. Treatment with
prednisolone higher than 15 mg per day was associated
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with 3.4-fold (95 % CI 2.01–5.86) increased risk of all-
cause mortality compared with non-use. Our findings of
probable perimortal bias, however, might suggest that the
hazard ratios reported in these previous studies are over-
estimates of the true effect.
An important finding of this study was the absence of an
association between both all-cause and cause-specific
mortality and GC doses lower than 5 mg per day. This may
reflect either a low risk of adverse events at this dose, or at
least a favourable balance between the harms and the
biologically plausible benefits through their anti-inflam-
matory effects [33]. This finding replicates similar findings
from Listing et al. [13] and del Rincon et al. [12], which
showed that doses lower than 5 and 8 mg PED, respec-
tively, had no association with mortality risk.
The strengths of this study are firstly its size, with nearly
3000 deaths in 16,762 patients. This meant the study had
greater power to detect differences in mortality rates and
allowed us to explore cause-specific mortality. We were
thus able to see an increased rate of respiratory deaths,
accepting the possibility of perimortal bias but also likely
driven by a causal increased risk of respiratory infection
[9]. Second, the study used linkage to the national mortality
register, providing robust and complete information on
cause of death for all patients in the study. Third, time-
varying covariates for DMARDs, NSAIDs and GCs, were
used to allow more accurate estimation compared to time-
independent variables for these drugs. Fourth, a range of
patterns of GC use were explored including GC use, GC
daily dose, and cumulative dose since cohort entry and
their categorical variables compared with non GC use in
association with risk of death. This approach allowed some
consideration of the impact of dose, duration and timing of
treatment on mortality risk. For example, the finding that
the highest current dose category was associated with very
high HRs for neoplasm, respiratory and other causes of
death, whilst the highest quartile had notably lower HRs,
suggests that high doses may be used at the end of life
when cumulative exposure is less of an issue. We also
explored possible perimortal bias which has not been
considered in previous studies. Moreover, we examined
oral GC therapy in association with cause-specific mor-
tality beyond CV mortality which has not been investigated
in previous studies.
There were some limitations with the study. The pre-
scription data from the CPRD dataset are reliable in terms
of drugs prescribed, but does not cover drugs prescribed in
secondary care only, such as biologic DMARDs, or over
the counter use of NSAIDs; although it has been shown
that biologic DMARDs are not associated with an
increased mortality compared to standard DMARDs [34].
In addition there may have been some exposure misclas-
sification because of assumptions in data preparation,
missing data, patient adherence, injectable steroids and
hospital administered GC, although the latter is likely to be
minimal as UK rheumatologists typically make recom-
mendations for oral GC treatment to GPs. Like all obser-
vational studies, the impact of confounding and bias
needed consideration. A range of possible confounders
were adjusted for, including time-varying exposure to
DMARDs and NSAIDS, and healthcare utilisation vari-
ables as surrogate measures of RA disease severity.
Although we didn’t have direct measures of disease
severity, previous studies that did adjust for clinician-re-
ported disease severity found a persistent association
between GC use and mortality [13]. It is thus likely that
there was some residual confounding by disease severity.
In terms of possible residual or unmeasured confounders
affecting the results, of which disease severity is one,
sensitivity analyses showed that these would need to be
very large to fully explain the results. So even though, for
example, high cumulative disease severity has been shown
to be associated with lymphoma [35] this would not fully
explain the results seen. Adjusting for the Charlson
comorbidity index at baseline was expected to control for
key comorbidities that contribute to an increased risk of
mortality. The main difference at baseline between GC
users and non-GC users was prior GC use, which was much
higher in GC users (44 vs. 6 %). It may have been that this
group was particularly susceptible to death, and any asso-
ciation between GC use and death may have been exag-
gerated. However, prior GC use was adjusted for so the
results should not be biased.
It is very challenging to understand the true causal
relationship between oral GC use and mortality from an
observational study due to the complex relationships
between the indication for treatment (that changes through
time) and the outcome, as well as the granularity of the data
from a population necessarily large to support the analysis.
Nonetheless, despite this blurring of causality by bias and
confounding, some important messages emerge. Doses
\5 mg were not associated with an increased risk of death.
This absent risk is not explained by confounding by disease
severity (where you would expect mortality to be higher in
the treated compared to non-treated), or by perimortal bias
where you would again expect an increased risk compared
to non-use. The lower dose-specific hazard ratios for car-
diovascular deaths compared to the hazard ratios seen for
the other causes of death raises the interesting hypothesis
that GC therapy might have a beneficial effect on cardio-
vascular mortality; yet a protective effect is impossible to
conclude with certainty as there is a statistically significant
increased risk for CV mortality with all doses above 5 mg.
Disentangling these complex factors is impossible, but the
large population observational research raises questions
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that can feed back into more targeted studies, both basic
science and epidemiological.
Conclusions
This study has found that GC use is associated with an
increased risk of death in RA, both all-cause and cause-
specific mortality, which is partially explained by peri-
mortal bias. Importantly, doses of below 5 mg PED were
not associated with an increased risk of death. There is a
suggestion that GCs may have a less harmful effect on CV
mortality compared to their association with other cause-
specific mortality, but targeted research is required to
examine this signal further.
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